Healthcare, Pharma & Life Sciences

Barcelona – October 18, 2026 -- United European Gastroenterology (UEG) has launched a Patient Representatives Advisory Board (PRAB) at UEG Week 2026, giving patient groups a formal channel into its public affairs activities across Europe.

PRAB builds on the 2025 Digestive Health Roundtable Manifesto

The board follows UEG's Digestive Health Roundtable 2025 and its Manifesto, which called for patients to be recognised as co-creators of digestive health policy, research and care.

The PRAB is a structured, independent advisory body. It will provide patient-centred input into UEG's public affairs work and, where relevant, its wider activities. It also creates a formal interface between UEG and the European patient community, with the aim of identifying challenges shared across digestive diseases.

Seoul – October 18, 2026 -- XellSmart's off-the-shelf Parkinson's cell therapy XS411 improved OFF-state motor scores by an average of more than 30 points at six months in all nine Phase I participants, and its 30-patient Phase II trial in China has completed enrollment.

The data were presented at the International Congress of Parkinson's Disease and Movement Disorders (MDS). The company says the results showed no dose-limiting toxicities, serious adverse events or adverse events related to XS411.

Phase I data show motor and imaging gains in nine patients

The single-arm, open-label trial used a 3+3 dose-escalation design across three cohorts. Participants had moderate-to-advanced disease, a mean duration of about 10 years, end-of-dose wearing-off and OFF-state Hoehn-Yahr stages of 3 to 4. Cells were transplanted into the bilateral posterior putamen.

Chicago – October 17, 2026 -- Early-tenure attrition at key Advocate Health sites fell from more than 70% to as low as 16% after the system added coaching for new hires. The result is one of several outcomes in a Brandon Hall Group review of 27 HCM Excellence Awards Excellence in Practice blueprints from 11 patient-care organizations. The firm presented the review at the WMHH Summit in Chicago.

Ascension and Acibadem tie human skills to observable behaviors

Ascension's Elevated Service Actions initiative translated service commitments into six observable behaviors. Leaders reinforced one behavior per month through huddles, staff meetings and coaching. The case reported a 13-point improvement in care team responsiveness and nearly five points in clinician interaction scores.

United States – October 17, 2026 -- Digital Diagnostics says its LumineticsCore system avoided 91% of unnecessary specialty visits in a pivotal clinical trial and cut time-to-follow-up for positive patients from 60 days to 5 days. The company made the claims in AdvaMed's "The Insight Series: AI & Digital Health," speaking through Jacque Engle, Vice President of Marketing & Communication, and Juli Goldstein, Vice President of Government Affairs & Market Access.

United States – October 17, 2026 -- Three-quarters of medical technology companies surveyed by AdvaMed report memory chip constraints, and 88 percent have seen price increases, as data-center demand squeezes supply of components used in 75 percent to 80 percent of medtech products (excluding personal protective equipment and consumables).

Survey shows allocation limits and procurement uncertainty across medtech

Beyond the 75 percent and 88 percent figures, 63 percent of respondents reported supplier allocation challenges or limited availability of specific components. Another 63 percent are uncertain they can procure enough memory chips, or products containing them, to avoid supply chain disruptions. Fifty-six percent said they are very concerned about overall memory chip supply chain stability.

Boston – October 17, 2026 -- AdvaMed will host The MedTech Conference October 18–21 in Boston, with programming across more than seven stages and over 20 focus areas and a keynote panel of three medtech chief executives.

Three medtech CEOs headline the featured keynote discussion

The featured session, "Pulse of Medtech: Where the Industry Is Going Next," brings together Mick Farrell of Resmed, Mike Mahoney of Boston Scientific and Ashley McEvoy of Insulet. John Babitt of EY will moderate.

Attendee list preview shows registrants across the value chain

AdvaMed has published the first 2026 Attendee List Preview. It includes CEOs, senior executives and professionals in business development, strategy, regulatory affairs, policy, investment and innovation. Registrants span leading global companies, emerging innovators, investors, service providers and other medtech ecosystem organizations.

United States – October 17, 2026 -- Nearly half of all heart attacks occur in patients classified as low risk under traditional factors such as age, cholesterol and family history, Elucid CEO Kelly Huang said in AdvaMed's "Insight Series: AI & Digital Health," arguing that AI must change clinical decisions rather than accelerate existing ones.

Elucid extracts plaque biology and blood-flow data from a single CT scan

Elucid's Plaque-IQ software analyzes an existing coronary CT angiogram to quantify plaque type and amount in coronary and carotid vessels. Its BioIntegrated FFR-CT predicts fractional flow reserve values along each vessel, using invasive FFR as ground truth. Plaque algorithms are validated against histology.

Huang said two patients can show identical plaque volume and similar stenosis yet carry different risk: one has lipid-rich, unstable plaque, the other calcified, stable plaque.

Boston – October 17, 2026 -- The MedTech Conference, running October 18–21 in Boston, will include 65 early- and mid-stage companies from the 2026 MedTech Innovator cohort, chosen from more than 1,800 applicants, alongside a program that makes digital health a core thread of the event, according to AdvaMed Digital Health Tech's new executive director.

Four policy areas drive the digital health agenda

AdvaMed Digital Health Tech's work spans regulation; payment and health care delivery; data access and stewardship; and cybersecurity. The executive director, whose background at AdvaMed is in coverage, payment and care delivery policy, said progress in each area depends on the other three.

Payment is a particular focus. AdvaMed is advocating for greater clarity and predictability around Medicare coverage and payment for software, AI and other digital health technologies.

Boston – October 17, 2026 -- AdvaMed is steering its more than 400 small and emerging medtech members toward The MedTech Conference, October 18–21 in Boston, where it expects over 4,000 attendees and 1,800 companies.

JC Scott, who has returned to the trade association as Chief Strategy Officer, also leads AdvaMed Accel as Executive Director. Accel is the association's dedicated division for emerging members, offering advocacy, access and community.

Partnering platform compresses investor outreach into days

Full Access attendees and Full Access exhibitors can use the Partnering platform to book one-on-one meetings with investors, collaborators, potential customers and strategic partners. Scott says conversations that might otherwise take months to arrange can happen over a few days. AdvaMed has published a 2026 investor list for preview.

Boston – October 17, 2026 -- The MedTech Conference (#MTC26) in Boston this October will host its first dedicated gathering for chief medical officers, open to CMOs at AdvaMed member companies, according to Bobby Patrick, AdvaMed's SVP of Government Affairs.

Patient Pavilion carries stories from 13 named medtech companies

The Patient Pavilion in the exhibit hall will anchor the patient programming throughout the week. Patients will share experiences with technologies from Abbott, BD, Dexcom, Edwards Lifesciences, Insulet, Medtronic, Philips, Resmed, Siemens Healthineers, Smith+Nephew, Stryker, Solventum, Vantive and other companies. Attendees can see Philips' portable MRI technology up close.

One featured story involves a patient named Brittany, whose severe sleep apnea diagnosis explained years of exhaustion. Treatment restored her energy, confidence and independence.